Trials / Completed
CompletedNCT00230789
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
A Multicenter, Multiphase, Single Arm, Open Label Study To Evaluate The Effects Of Tolterodine ER In Conjunction With Behavioral Intervention On Subject Satisfaction And Over- Active Bladder Symptoms (Urgency Urinary Incontinence (UUI), Urgency, Frequency) In Overactive Bladder Subjects Who Were Dissatisfied With Their Most Recent Antimuscarinic OAB Medication Therapy.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 417 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolterodine ER 4 mg QD | |
| BEHAVIORAL | OAB Patient Behavioral Training Material |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2005-10-03
- Last updated
- 2021-01-27
Locations
51 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00230789. Inclusion in this directory is not an endorsement.